TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Patient-Centered Approach to Advance Care Planning of Patients With End Stage Heart Failure and Renal Disease
Brief Summary: Based on theories regarding decision-making and patient education the investigators have developed Patient-Centered Advance Care Planning (PC-ACP). This intervention is designed to improve patient and surrogate knowledge of ACP, increase the congruence between patient and surrogate in treatment decisions, decrease the patient's and surrogate's conflict in making such decisions, and increase the consistency between patient preferences and the actual care they receive. The ACP intervention is conducted with the patient in the presence of the surrogate.


Options:
A: Arm Label: Control; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: Placebo | Arm Label: Intervention; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Educational Intervention, Behavioral: Placebo | Intervention Type: BEHAVIORAL; Name: Educational Intervention; Assigned to Arm(s): Intervention | Intervention Type: BEHAVIORAL; Name: Placebo; Assigned to Arm(s): Control, Intervention
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Health Literacy-Focused High Blood Pressure Intervention | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Health Literacy-Focused High Blood Pressure Intervention | Intervention Type: BEHAVIORAL; Name: Health Literacy-Focused High Blood Pressure Intervention; Assigned to Arm(s): 1, 2
C: Intervention Type: BEHAVIORAL; Name: Patient-Centered Advance Care Planning; Assigned to Arm(s): N/A
D: Arm Label: Diabetes Telemonitoring (DTM); Type: EXPERIMENTAL; Interventions: Behavioral: Diabetes Telemonitoring | Arm Label: Comprehensive Outpatient Management (COM); Type: ACTIVE_COMPARATOR; Interventions: Other: Comprehensive Outpatient Management | Intervention Type: OTHER; Name: Comprehensive Outpatient Management; Assigned to Arm(s): Comprehensive Outpatient Management (COM) | Intervention Type: BEHAVIORAL; Name: Diabetes Telemonitoring; Assigned to Arm(s): Diabetes Telemonitoring (DTM)

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Patient-Centered Approach to Advance Care Planning of Patients With End Stage Heart Failure and Renal Disease
Brief Summary: Based on theories regarding decision-making and patient education the investigators have developed Patient-Centered Advance Care Planning (PC-ACP). This intervention is designed to improve patient and surrogate knowledge of ACP, increase the congruence between patient and surrogate in treatment decisions, decrease the patient's and surrogate's conflict in making such decisions, and increase the consistency between patient preferences and the actual care they receive. The ACP intervention is conducted with the patient in the presence of the surrogate.


Options:
A: Arm Label: ADAPT Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: ADAPT Intervention | Arm Label: Enhanced usual care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: ADAPT Intervention; Assigned to Arm(s): ADAPT Intervention
B: Arm Label: Usual heart failure care; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Usual care + palliative care; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Usual heart failure care, Behavioral: Interdisciplinary palliative care | Intervention Type: BEHAVIORAL; Name: Usual heart failure care; Assigned to Arm(s): Usual care + palliative care | Intervention Type: BEHAVIORAL; Name: Interdisciplinary palliative care; Assigned to Arm(s): Usual care + palliative care
C: Arm Label: Goc Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: goals of care | Arm Label: usual care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: goals of care; Assigned to Arm(s): Goc Intervention
D: Intervention Type: BEHAVIORAL; Name: Patient-Centered Advance Care Planning; Assigned to Arm(s): N/A

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Patient-Centered Approach to Advance Care Planning of Patients With End Stage Heart Failure and Renal Disease
Brief Summary: Based on theories regarding decision-making and patient education the investigators have developed Patient-Centered Advance Care Planning (PC-ACP). This intervention is designed to improve patient and surrogate knowledge of ACP, increase the congruence between patient and surrogate in treatment decisions, decrease the patient's and surrogate's conflict in making such decisions, and increase the consistency between patient preferences and the actual care they receive. The ACP intervention is conducted with the patient in the presence of the surrogate.


Options:
A: Arm Label: Group Based; Type: EXPERIMENTAL; Interventions: Behavioral: Group-Based (GB) Intervention | Arm Label: Home-Based; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Home-Based (HB) Intervention | Arm Label: Standard Care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Group-Based (GB) Intervention; Assigned to Arm(s): Group Based | Intervention Type: BEHAVIORAL; Name: Home-Based (HB) Intervention; Assigned to Arm(s): Home-Based
B: Arm Label: SystemCHANGE; Type: EXPERIMENTAL; Interventions: Behavioral: SystemCHANGE | Arm Label: Patient-education attention-control; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Patient-education attention control | Intervention Type: BEHAVIORAL; Name: SystemCHANGE; Assigned to Arm(s): SystemCHANGE | Intervention Type: BEHAVIORAL; Name: Patient-education attention control; Assigned to Arm(s): Patient-education attention-control
C: Intervention Type: BEHAVIORAL; Name: Patient-Centered Advance Care Planning; Assigned to Arm(s): N/A
D: Arm Label: ATSM + Health Coach and CKD Registry; Type: EXPERIMENTAL; Interventions: Behavioral: CKD Registry, Behavioral: ATSM + Health Coach | Arm Label: CKD Registry; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: CKD Registry | Arm Label: ATSM + Health Coach; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: ATSM + Health Coach | Arm Label: Usual Care (no interventions); Type: PLACEBO_COMPARATOR; Interventions: Behavioral: Usual care | Intervention Type: BEHAVIORAL; Name: CKD Registry; Assigned to Arm(s): ATSM + Health Coach and CKD Registry, CKD Registry | Intervention Type: BEHAVIORAL; Name: ATSM + Health Coach; Assigned to Arm(s): ATSM + Health Coach, ATSM + Health Coach and CKD Registry | Intervention Type: BEHAVIORAL; Name: Usual care; Assigned to Arm(s): Usual Care (no interventions)

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Team Model of Hypertension Care in African Americans
Brief Summary: This Team Education and Adherence Monitoring (TEAM) trial will evaluate the cost-effectiveness of a pharmacy-based intervention in a randomized controlled trial involving 597 treated hypertensive African American patients in five Wisconsin cities. The study involves 28 community pharmacies (14 intervention, 14 control) owned by two pharmacy corporations. Intervention pharmacists and pharmacy technicians implemented a 6-month blood pressure (BP) monitoring program that involved working together as a team with patients and their physicians to achieve improved medication adherence, healthy lifestyles, drug therapy, and hypertension control.


Options:
A: Arm Label: Standard Care; Type: OTHER; Interventions: Other: Standard care | Arm Label: Standard Care and Pharmaceutical Care; Type: OTHER; Interventions: Other: Standard care and Pharmaceutical care | Intervention Type: OTHER; Name: Standard care and Pharmaceutical care; Assigned to Arm(s): Standard Care and Pharmaceutical Care | Intervention Type: OTHER; Name: Standard care; Assigned to Arm(s): Standard Care
B: Arm Label: TEAM Care; Type: EXPERIMENTAL; Interventions: Behavioral: Pharmacy TEAM monitoring and counseling | Arm Label: Usual Care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Pharmacy TEAM monitoring and counseling; Assigned to Arm(s): TEAM Care
C: Arm Label: Usual Care; Type: ACTIVE_COMPARATOR; Interventions: Other: Usual Care | Arm Label: Enhanced pharmacist care; Type: EXPERIMENTAL; Interventions: Other: Enhanced pharmacist care | Intervention Type: OTHER; Name: Enhanced pharmacist care; Assigned to Arm(s): Enhanced pharmacist care | Intervention Type: OTHER; Name: Usual Care; Assigned to Arm(s): Usual Care
D: Arm Label: Usual Care; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Intervention Group; Type: EXPERIMENTAL; Interventions: Behavioral: Pharmaceutical care program for antidepressant treatment | Intervention Type: BEHAVIORAL; Name: Pharmaceutical care program for antidepressant treatment; Assigned to Arm(s): Intervention Group

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Pharmacokinetics and Dynamics in Patients Randomized to Once Daily Awakening and Sedated According to Standardized Algorithm
Brief Summary: Certain methods of sedation increase the duration of respiratory failure. Two strategies, a nursing- implemented sedation algorithm and daily interruption of sedatives, decrease length of mechanical ventilation compared to "conventional care" but have not been compared to each other. The reason certain methods of sedation lead to prolonged respiratory failure is unknown but may be related to altered pharmacokinetics and dynamics that are unique to critically ill patients. Critically ill patients receive substantial doses of sedatives over prolonged periods. The impact of these management strategies on short- and long-term psychiatric complications are unknown. The study seeks to test the central hypothesis that sedation practices impact strongly on outcome of respiratory failure and psychiatric complications. The three specific aims are (1) to compare two sedation strategies (protocol directed sedation and daily interruption of sedatives), (2) to examine the prevalence of psychiatric complications, and (3) to compute the pharmacokinetics of commonly used sedatives and narcotics.

These aims will be achieved by enrolling critically ill patients in a prospective randomized trial comparing the above mentioned sedation strategies, and assessing sedation level as well as delirium throughout the duration of respiratory failure. Sedative plasma levels will be measured, and pharmacokinetics computed. Psychiatric morbidity will be assessed by administration of validated questionnaires.


Options:
A: Arm Label: No sedatation intervention; Type: OTHER; Interventions: Procedure: Sedation or no sedation during mechanical ventilation | Intervention Type: PROCEDURE; Name: Sedation or no sedation during mechanical ventilation; Assigned to Arm(s): No sedatation intervention
B: Intervention Type: PROCEDURE; Name: Daily interruption of sedation versus sedation algorithm; Assigned to Arm(s): N/A
C: Arm Label: Dexmedetomidine; Type: EXPERIMENTAL; Interventions: Drug: Dexmedetomidine HCL Injection | Arm Label: Midazolam; Type: ACTIVE_COMPARATOR; Interventions: Drug: Midazolam Injection | Intervention Type: DRUG; Name: Dexmedetomidine HCL Injection; Assigned to Arm(s): Dexmedetomidine | Intervention Type: DRUG; Name: Midazolam Injection; Assigned to Arm(s): Midazolam
D: Arm Label: Dexmedetomidine group; Type: ACTIVE_COMPARATOR; Interventions: Drug: Dexmedetomidine | Arm Label: Lorazepam group; Type: ACTIVE_COMPARATOR; Interventions: Drug: Lorazepam | Intervention Type: DRUG; Name: Dexmedetomidine; Assigned to Arm(s): Dexmedetomidine group | Intervention Type: DRUG; Name: Lorazepam; Assigned to Arm(s): Lorazepam group

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effect of Increased Convective Clearance by On-line Hemodiafiltration on All Cause and Cardiovascular Mortality in Chronic Hemodialysis Patients: The Dutch Convective Transport Study (CONTRAST)
Brief Summary: The purpose of this study is to compare the effect of low flux hemodialysis with online hemodiafiltration on all cause mortality and a combination of cardiovascular morbidity and mortality in chronic hemodialysis patients.


Options:
A: Arm Label: 1: low flux hemodialysis; Type: OTHER; Interventions: Procedure: low flux hemodialysis | Arm Label: 2 on-line hemodiafiltration; Type: ACTIVE_COMPARATOR; Interventions: Procedure: on-line hemodiafiltration | Intervention Type: PROCEDURE; Name: on-line hemodiafiltration; Assigned to Arm(s): 2 on-line hemodiafiltration | Intervention Type: PROCEDURE; Name: low flux hemodialysis; Assigned to Arm(s): 1: low flux hemodialysis
B: Arm Label: Low normal pH (arterial pH 7.36-7.38); Type: ACTIVE_COMPARATOR; Interventions: Drug: ammonium chloride or sodium citrate/citric acid | Arm Label: High Normal pH (arterial pH 7.44-7.46); Type: ACTIVE_COMPARATOR; Interventions: Drug: Sodium citrate/citratic acid | Intervention Type: DRUG; Name: ammonium chloride or sodium citrate/citric acid; Assigned to Arm(s): Low normal pH (arterial pH 7.36-7.38) | Intervention Type: DRUG; Name: Sodium citrate/citratic acid; Assigned to Arm(s): High Normal pH (arterial pH 7.44-7.46)
C: Arm Label: Rosuvastatin 10mg; Type: EXPERIMENTAL; Interventions: Drug: 10mg Rosuvastatin | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: 10mg Rosuvastatin; Assigned to Arm(s): Rosuvastatin 10mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Conventional hemodialysis; Type: ACTIVE_COMPARATOR; Interventions: Device: Conventional hemodialysis | Arm Label: Frequent hemodialysis; Type: EXPERIMENTAL; Interventions: Device: Frequent hemodialysis | Intervention Type: DEVICE; Name: Conventional hemodialysis; Assigned to Arm(s): Conventional hemodialysis | Intervention Type: DEVICE; Name: Frequent hemodialysis; Assigned to Arm(s): Frequent hemodialysis

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The "EXTEND" Study: A Randomized, Double-blind, Parallel-group, Phase III b, Multi-centre Study Evaluating Extended Prophylactic Treatment With Melagatran/Ximelagatran Versus Enoxaparin for the Prevention of Venous Thromboembolic Events in Patients Undergoing Elective Hip Replacement or Hip Fracture Surgery.
Brief Summary: This study is being carried out to study the efficacy and safety of treatment with melagatran injection followed by ximelagatran tablets in preventing blood clots, compared with enoxaparin for a period of 5-6 weeks. A separate visit, independent from the study will be done approximately 6 months after the surgery.


Options:
A: Intervention Type: DRUG; Name: EXANTA; Assigned to Arm(s): N/A
B: Arm Label: Arm 1; Type: EXPERIMENTAL; Interventions: Drug: Rivaroxaban (BAY59-7939) | Arm Label: Arm 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Enoxaparin | Intervention Type: DRUG; Name: Rivaroxaban (BAY59-7939); Assigned to Arm(s): Arm 1 | Intervention Type: DRUG; Name: Enoxaparin; Assigned to Arm(s): Arm 2
C: Arm Label: Apixaban, 2.5 mg BID + Placebo; Type: EXPERIMENTAL; Interventions: Drug: Apixaban, Drug: Enoxaparin-matching placebo | Arm Label: Enoxaparin, 40 mg QD + Placebo; Type: ACTIVE_COMPARATOR; Interventions: Drug: Enoxaparin, Drug: Apixaban-matching placebo | Intervention Type: DRUG; Name: Enoxaparin; Assigned to Arm(s): Enoxaparin, 40 mg QD + Placebo | Intervention Type: DRUG; Name: Apixaban; Assigned to Arm(s): Apixaban, 2.5 mg BID + Placebo | Intervention Type: DRUG; Name: Enoxaparin-matching placebo; Assigned to Arm(s): Apixaban, 2.5 mg BID + Placebo | Intervention Type: DRUG; Name: Apixaban-matching placebo; Assigned to Arm(s): Enoxaparin, 40 mg QD + Placebo
D: Arm Label: Arm 1; Type: EXPERIMENTAL; Interventions: Drug: Rivaroxaban (BAY59-7939) | Arm Label: Arm 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Enoxaparin | Intervention Type: DRUG; Name: Rivaroxaban (BAY59-7939); Assigned to Arm(s): Arm 1 | Intervention Type: DRUG; Name: Enoxaparin; Assigned to Arm(s): Arm 2

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A 6-Month Double-Blind, Double-Dummy, Randomized, Parallel Group, Multicenter Efficacy & Safety Study of SYMBICORT® pMDI 2 x 160/4.5 µg & 80/4.5 µg Bid Compared to Formoterol TBH, Budesonide pMDI (& the Combination) & Placebo in COPD Patients
Brief Summary: The purpose of this study is to compare a combination asthma drug (Symbicort) with its two components, budesonide and formoterol, taken individually or in combination, and with placebo in the long-term maintenance treatment of patients with chronic obstructive pulmonary disease (COPD)


Options:
A: Arm Label: GSK573719/GW642444; Type: EXPERIMENTAL; Interventions: Drug: 125/25 mcg once-daily GSK573719/GW642444 | Arm Label: GSK573719; Type: EXPERIMENTAL; Interventions: Drug: 125mcg once-daily GSK573719 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo once-daily | Intervention Type: DRUG; Name: 125/25 mcg once-daily GSK573719/GW642444; Assigned to Arm(s): GSK573719/GW642444 | Intervention Type: DRUG; Name: 125mcg once-daily GSK573719; Assigned to Arm(s): GSK573719 | Intervention Type: DRUG; Name: Placebo once-daily; Assigned to Arm(s): Placebo
B: Arm Label: FF/GW642444 Inhalation Powder; Type: EXPERIMENTAL; Interventions: Drug: FF/GW642444 Inhalation Powder | Arm Label: FF Inhalation Powder; Type: EXPERIMENTAL; Interventions: Drug: FF Inhalation Powder | Arm Label: GW642444 Inhalation Powder; Type: EXPERIMENTAL; Interventions: Drug: GW642444 Inhalation Powder | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: FF/GW642444 Inhalation Pwdr; Type: EXPERIMENTAL; Interventions: Drug: FF/GW642444 Inhalation Powder | Intervention Type: DRUG; Name: FF/GW642444 Inhalation Powder; Assigned to Arm(s): FF/GW642444 Inhalation Powder, FF/GW642444 Inhalation Pwdr | Intervention Type: DRUG; Name: FF Inhalation Powder; Assigned to Arm(s): FF Inhalation Powder | Intervention Type: DRUG; Name: GW642444 Inhalation Powder; Assigned to Arm(s): GW642444 Inhalation Powder | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Intervention Type: DRUG; Name: Budesonide/formoterol pMDI; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Budesonide pMDI; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Formoterol Turbuhaler; Assigned to Arm(s): N/A
D: Arm Label: NVA237 100 µg; Type: EXPERIMENTAL; Interventions: Drug: NVA237 100 µg | Arm Label: NVA237 200 µg; Type: EXPERIMENTAL; Interventions: Drug: NVA237 200 µg | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: NVA237 100 µg; Assigned to Arm(s): NVA237 100 µg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: NVA237 200 µg; Assigned to Arm(s): NVA237 200 µg

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A 6-Month Double-Blind, Double-Dummy, Randomized, Parallel Group, Multicenter Efficacy & Safety Study of SYMBICORT® pMDI 2 x 160/4.5 µg & 80/4.5 µg Bid Compared to Formoterol TBH, Budesonide pMDI (& the Combination) & Placebo in COPD Patients
Brief Summary: The purpose of this study is to compare a combination asthma drug (Symbicort) with its two components, budesonide and formoterol, taken individually or in combination, and with placebo in the long-term maintenance treatment of patients with chronic obstructive pulmonary disease (COPD)


Options:
A: Intervention Type: DRUG; Name: Budesonide/formoterol pMDI; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Budesonide pMDI; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Formoterol Turbuhaler; Assigned to Arm(s): N/A
B: Intervention Type: DRUG; Name: fluticasone 500 mcg; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: fluticasone 500 mcg + salmeterol 50 mcg; Assigned to Arm(s): N/A
C: Intervention Type: DRUG; Name: Budesonide/formoterol pMDI; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Formoterol Turbuhaler; Assigned to Arm(s): N/A
D: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: terbutaline sulfate (Bricasol) | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: budesonide (Pulmicort), Drug: terbutaline sulfate (Bricasol) | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Drug: budesonide/formoterol (Symbicort), Drug: terbutaline sulfate (Bricasol) | Intervention Type: DRUG; Name: budesonide/formoterol (Symbicort); Assigned to Arm(s): 3 | Intervention Type: DRUG; Name: budesonide (Pulmicort); Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: terbutaline sulfate (Bricasol); Assigned to Arm(s): 1, 2, 3

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A 6-Month Double-Blind, Double-Dummy, Randomized, Parallel Group, Multicenter Efficacy & Safety Study of SYMBICORT® pMDI 2 x 160/4.5 µg & 80/4.5 µg Bid Compared to Formoterol TBH, Budesonide pMDI (& the Combination) & Placebo in COPD Patients
Brief Summary: The purpose of this study is to compare a combination asthma drug (Symbicort) with its two components, budesonide and formoterol, taken individually or in combination, and with placebo in the long-term maintenance treatment of patients with chronic obstructive pulmonary disease (COPD)


Options:
A: Intervention Type: DRUG; Name: Budesonide/formoterol pMDI; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Budesonide pMDI; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Formoterol Turbuhaler; Assigned to Arm(s): N/A
B: Arm Label: Indacaterol 300 μg plus placebo to formoterol; Type: EXPERIMENTAL; Interventions: Drug: Indacaterol, Drug: Placebo to formoterol | Arm Label: Indacaterol 600 μg plus placebo to formoterol; Type: EXPERIMENTAL; Interventions: Drug: Indacaterol, Drug: Placebo to formoterol | Arm Label: Formoterol 12 μg plus placebo to indacaterol; Type: ACTIVE_COMPARATOR; Interventions: Drug: Formoterol, Drug: Placebo to indacaterol | Arm Label: Placebo to indacaterol plus placebo to formoterol; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo to indacaterol, Drug: Placebo to formoterol | Intervention Type: DRUG; Name: Indacaterol; Assigned to Arm(s): Indacaterol 300 μg plus placebo to formoterol, Indacaterol 600 μg plus placebo to formoterol | Intervention Type: DRUG; Name: Formoterol; Assigned to Arm(s): Formoterol 12 μg plus placebo to indacaterol | Intervention Type: DRUG; Name: Placebo to indacaterol; Assigned to Arm(s): Formoterol 12 μg plus placebo to indacaterol, Placebo to indacaterol plus placebo to formoterol | Intervention Type: DRUG; Name: Placebo to formoterol; Assigned to Arm(s): Indacaterol 300 μg plus placebo to formoterol, Indacaterol 600 μg plus placebo to formoterol, Placebo to indacaterol plus placebo to formoterol
C: Intervention Type: DRUG; Name: Salmeterol 50mcg/ Fluticasone Propionate 500mcg; Assigned to Arm(s): N/A
D: Arm Label: Indacaterol 150 μg; Type: EXPERIMENTAL; Interventions: Drug: Indacaterol 150 μg, Drug: Placebo to Salmeterol | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo to Indacaterol, Drug: Placebo to Salmeterol | Arm Label: Salmeterol 50 μg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Salmeterol 50 μg, Drug: Placebo to Indacaterol | Intervention Type: DRUG; Name: Indacaterol 150 μg; Assigned to Arm(s): Indacaterol 150 μg | Intervention Type: DRUG; Name: Salmeterol 50 μg; Assigned to Arm(s): Salmeterol 50 μg | Intervention Type: DRUG; Name: Placebo to Indacaterol; Assigned to Arm(s): Placebo, Salmeterol 50 μg | Intervention Type: DRUG; Name: Placebo to Salmeterol; Assigned to Arm(s): Indacaterol 150 μg, Placebo

Answer: A